The monoethylglycinexylidide test does not impair psychometric performance in patients with chronic hepatitis or cirrhosis

Therapeutic Drug Monitoring

Volumn 22, Issue 4, 2000, Pages 371-374

  Botta, Federica ^a   Giannini, Edoardo ^a   Fasoli, Alberto ^a   Romagnoli, Paola ^a   Risso, Domenico ^b   Testa, Roberto ^a,c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Gastroenterology Unit   (Italy)

Author keywords

Chronic liver disease; MEGX test; Portosystemic encephalopathy; Psychometric test

Indexed keywords

DEETHYLLIDOCAINE; LIDOCAINE;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DISORIENTATION; DRUG MONITORING; DRUG SAFETY; FEMALE; HEART RATE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; MEAN ARTERIAL PRESSURE; PARESTHESIA; PERFORMANCE; PRIORITY JOURNAL; PSYCHOMETRY; RISK BENEFIT ANALYSIS; TINNITUS; VERTIGO;

ADULT; AGED; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATITIS, CHRONIC; HUMANS; LIDOCAINE; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 0033855590     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200008000-00001     Document Type: Article

References (16)

1. Local anesthetics
2. Effect of lidocaine on ventricular arrhythmias in patients with coronary heart disease
3. Monoethylglycinexylidide formation kinetics. A novel approach to assessment of liver function
4. Assessment of pre-transplant prognosis in patients with cirrhosis
5. Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis
6. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease
7. Predictors of one-year pretransplant survival in patients with cirrhosis
8. Review article: Quantitative tests of liver function
9. Use of hepatic lidocaine metabolism to monitor patients with chronic liver disease
10. The low-dose monoethylglycinexylidide test: Assessment of liver function with fewer side effects
11. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparent healthy, ambulant, non-shunted patients with cirrhosis
12. The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects
13. Principles of therapeutics
14. Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis and cirrhosis
15. Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration